治愈乙肝或许可能，或许啊

benben00

Two randomised controlled studies of PEG IFN in patients with HBeAg-positive and HBeAg-negative chronic hepatitis B have confirmed its efficacy with 36 and 43% of 24-week post-treatment response, respectively    [35,36].  Interestingly, relatively high rates of HBsAg loss, which are associated with complete and sustained remission of the disease, were observed in both studies
[3% (HBeAg-positive) and 4% (HBeAg-negative)] as compared with < 1% in patients treated with lamivudine.
Recently, follow-up data of this trial reported responses at 3 years post treatment    [38]. Biochemical and virologic responses at 3 years post treatment were stable following treatment with either PEG IFN monotherapy or in combination
with lamivudine. In addition, at 3 and 4 years post treatment, an increase in HBsAg loss was observed in 8 and 11% of patients, respectively.

今天看文献时看到的，PEG-干扰素和拉米夫定合用，高达11%的患者HBsAg消失---也就是治愈。




(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

benben00

Tenofovir
Two multi-centre, randomised,
double-blind, Phase III clinical trials evaluated the safety and efficacy of 300 mg tenofovir versus 10 mg adefovir at 48 weeks in subjects with HBeAg-positive (n = 266) and HBeAg-negative (n = 375) chronic HBV    [57,58]. In HBeAg-positive, chronic HBV patients, tenofovir clearly demonstrated superior efficacy to adefovir through 48 weeks as illustrated by the higher percentage of undetectable HBV DNA levels [74% (tenofovir) versus 12% (adefovir)] and normalisation of ALT levels [69% (tenofovir) versus 54% (adefovir)]. Interestingly, HBsAg loss was observed in 3% of patients after 48 weeks of tenofovir therapy. Similar results were observed in HBeAg-negative chronic HBV patients: tenofovir showed a higher antiviral efficacy than adefovir after 48 weeks of therapy.

Tenofovir 3%的治愈

逝水有声

不会吧？到目前为止全世界还没一例慢肝治好的病例呢！如果真能治好的话那乙肝也不是什么世界性难题了！

interdetect

ru guo shi zhen de  jiu hao le

富贵数字

在哪看的？

中国成都

支持！